Hofseth BioCare ASA

OB:HBC Stock Report

Market Cap: NOK 534.4m

Hofseth BioCare Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Jon Odegard

Chief executive officer

NOK 2.8m

Total compensation

CEO salary percentage58.6%
CEO tenure2.3yrs
CEO ownershipn/a
Management average tenure3.8yrs
Board average tenure2.5yrs

Recent management updates

Recent updates

Here's Why Hofseth BioCare (OB:HBC) Can Afford Some Debt

Apr 01
Here's Why Hofseth BioCare (OB:HBC) Can Afford Some Debt

We Think Hofseth BioCare (OB:HBC) Has A Fair Chunk Of Debt

Dec 22
We Think Hofseth BioCare (OB:HBC) Has A Fair Chunk Of Debt

Health Check: How Prudently Does Hofseth BioCare (OB:HBC) Use Debt?

Apr 28
Health Check: How Prudently Does Hofseth BioCare (OB:HBC) Use Debt?

Hofseth BioCare (OB:HBC) Is Carrying A Fair Bit Of Debt

Oct 16
Hofseth BioCare (OB:HBC) Is Carrying A Fair Bit Of Debt

Is Hofseth BioCare (OB:HBC) Using Debt Sensibly?

Feb 24
Is Hofseth BioCare (OB:HBC) Using Debt Sensibly?

How Much Of Hofseth BioCare ASA (OB:HBC) Do Insiders Own?

Jan 28
How Much Of Hofseth BioCare ASA (OB:HBC) Do Insiders Own?

Are Insiders Buying Hofseth BioCare ASA (OB:HBC) Stock?

Dec 25
Are Insiders Buying Hofseth BioCare ASA (OB:HBC) Stock?

Hofseth BioCare (OB:HBC) Shareholders Have Enjoyed A Whopping 339% Share Price Gain

Nov 20
Hofseth BioCare (OB:HBC) Shareholders Have Enjoyed A Whopping 339% Share Price Gain

CEO Compensation Analysis

How has Jon Odegard's remuneration changed compared to Hofseth BioCare's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-NOK 133m

Jun 30 2024n/an/a

-NOK 121m

Mar 31 2024n/an/a

-NOK 98m

Dec 31 2023NOK 3mNOK 2m

-NOK 107m

Sep 30 2023n/an/a

-NOK 93m

Jun 30 2023n/an/a

-NOK 105m

Mar 31 2023n/an/a

-NOK 140m

Dec 31 2022NOK 3mNOK 1m

-NOK 137m

Sep 30 2022n/an/a

-NOK 136m

Jun 30 2022n/an/a

-NOK 139m

Mar 31 2022n/an/a

-NOK 135m

Dec 31 2021n/an/a

-NOK 126m

Sep 30 2021n/an/a

-NOK 120m

Jun 30 2021n/an/a

-NOK 115m

Mar 31 2021n/an/a

-NOK 111m

Dec 31 2020NOK 2mNOK 695k

-NOK 102m

Sep 30 2020n/an/a

-NOK 104m

Jun 30 2020n/an/a

-NOK 90m

Mar 31 2020n/an/a

-NOK 86m

Dec 31 2019NOK 2mNOK 660k

-NOK 89m

Sep 30 2019n/an/a

-NOK 79m

Jun 30 2019n/an/a

-NOK 81m

Mar 31 2019n/an/a

-NOK 83m

Dec 31 2018NOK 2mNOK 702k

-NOK 85m

Sep 30 2018n/an/a

-NOK 74m

Jun 30 2018n/an/a

-NOK 66m

Mar 31 2018n/an/a

-NOK 66m

Dec 31 2017NOK 2mNOK 2m

-NOK 16m

Compensation vs Market: Jon's total compensation ($USD256.71K) is about average for companies of similar size in the Norwegian market ($USD300.00K).

Compensation vs Earnings: Jon's compensation has been consistent with company performance over the past year.

CEO

Jon Odegard

2.3yrs

Tenure

NOK 2,841,000

Compensation

Mr. Jon Olav Odegard had been Chief Financial Officer of Hofseth BioCare ASA since August 29, 2016 until 2022 and serves as its Chief Executive Officer since August 1, 2022 and was its Chief Executive Offi...

Leadership Team

NamePositionTenureCompensationOwnership
Jon Odegard
Chief Executive Officer2.3yrsNOK 2.84mno data
Bomi Framroze
Chief Scientific Officer14.8yrsNOK 9.44m1.26%
NOK 6.8m
James Berger
Chief Commercial Officer3.8yrsNOK 501.00kno data
Angelika Florvaag
Chief Quality Officer3.8yrsNOK 1.26mno data

3.8yrs

Average Tenure

Experienced Management: HBC's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Crawford Linden Currie
Director2.8yrsNOK 96.00kno data
Roger Hofseth
Director2.3yrsNOK 96.00kno data
Maria Bech
Directorless than a yearno datano data
Amy Novogratz
Independent Director2.9yrsno datano data
Christoph Baldegger
Independent Director9.8yrsNOK 116.00kno data
Linda Hoff
Chair of the Boardless than a yearno datano data

2.5yrs

Average Tenure

53yo

Average Age

Experienced Board: HBC's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.